XORTX Therapeutics Inc. XRTX.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · xortx.com
XORTX Therapeutics Inc. is a Canadian late-stage clinical pharmaceutical company focused on developing therapies that modulate uric acid pathways to treat kidney diseases and metabolic conditions. Its pipeline includes XRx-026 (Phase 3) for gout, XRx-008 (Phase 2) for autosomal dominant polycystic kidney disease, and XRx-101 (Phase 2) for acute kidney injury associated with respiratory virus infection. The company is headquartered in Calgary, Alberta.
Key ratios
ReturnOnAssets TTM -0.47
ReturnOnAssets 2025 -0.47
ReturnOnAssets 2024 -0.34
ReturnOnAssets 2023 -0.35
ReturnOnEquity TTM -0.98
ReturnOnEquity 2025 -0.98
ReturnOnEquity 2024 -0.83
ReturnOnEquity 2023 -0.37
Recent news
XORTX Announces Director Resignation
2026-07-31 · GlobeNewswire
XORTX Appoints New Director
2026-07-29 · GlobeNewswire
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
2026-06-15 · XORTX Therapeutics
XORTX Confirms Effective Date of Share Consolidation
2026-04-01 · XORTX Therapeutics
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
2026-02-04 · XORTX Therapeutics